TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23430102

Group type: EXPERIMENTAL
Intervention: Age + trunk flexor endurance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disability + hip extensor strength
Number of subjects: 0
Study: 21998479

Group type: EXPERIMENTAL
Intervention: Valacyclovir 1.5 g twice daily for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Acyclovir 400 mg twice daily for 12 weeks
Number of subjects: 32
Study: 18444745

Group type: EXPERIMENTAL
Intervention: Making choices among consumer goods or college course options
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thinking about options without making choices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anticipating the choice task as enjoyable
Number of subjects: 0
Study: 16927137

Group type: EXPERIMENTAL
Intervention: IV pantoprazole (40 mg once daily for 7 days)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Oral pantoprazole (40 mg once daily for 7 days)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: IV/oral pantoprazole
Number of subjects: 78
Study: 15742550

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (90 mg subcutaneously twice daily) plus optimized background regimen
Number of subjects: 995

Group type: COMPARATOR
Intervention: Optimized antiretroviral regimen alone (control group)
Number of subjects: 995
Study: 11269460

Group type: EXPERIMENTAL
Intervention: Crystalloid cardioplegia
Number of subjects: 50

Group type: COMPARATOR
Intervention: Blood cardioplegia
Number of subjects: 50
Study: 9849404

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN-alpha 2b) as adjuvant therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN-alpha 2b)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation (control)
Number of subjects: 0
Study: 10319136

Group type: EXPERIMENTAL
Intervention: Formulation A (0.5 mg oral digoxin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Formulation B (0.5 mg oral digoxin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Formulation C (0.5 mg oral digoxin, standard)
Number of subjects: 12
Study: 2687956

Group type: EXPERIMENTAL
Intervention: Combined modality treatment with radiotherapy and chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thoracic radiation with chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined modality treatment after resection of rectal cancer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation and concurrent 5-fluorouracil for squamous cancers of the anal canal
Number of subjects: 0
Study: 53659

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 1‐25 megaunits of penicillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local wound irrigation with 100mg of tetracycline in solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: No antibiotics (control group)
Number of subjects: 0
Study: 30714820

Group type: EXPERIMENTAL
Intervention: Combined regimen of immediate release (IR) and extended release (ER) methylphenidate taken at the same time
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single extended release (ER) methylphenidate dose
Number of subjects: 0
Study: 29087804

Group type: EXPERIMENTAL
Intervention: Extraction treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Air-rotor stripping (ARS) treatment
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Non-extraction treatment
Number of subjects: 44
Study: 25373438

Group type: EXPERIMENTAL
Intervention: Prophylactic dose low-molecular-weight heparin (LMWH) for 21 days
Number of subjects: 378

Group type: COMPARATOR
Intervention: Saline placebo injections for 21 days
Number of subjects: 378
Study: 23874588

Group type: EXPERIMENTAL
Intervention: Soy isoflavone capsules (80 mg/d total isoflavones, 51 mg/d aglucon units)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 21334240

Group type: EXPERIMENTAL
Intervention: Lidocaine (50 mg Xilonibsa 10% before examination)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 109
Study: 19209034

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 147
Study: 17109339

Group type: EXPERIMENTAL
Intervention: Cyclosporin A treatment for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standardized antiretroviral therapy (ART)
Number of subjects: 0
Study: 14716265

Group type: EXPERIMENTAL
Intervention: 1 mm thick MTA
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 2 mm thick MTA
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3 mm thick MTA
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 4 mm thick MTA
Number of subjects: 64
Study: 11239186

Group type: EXPERIMENTAL
Intervention: NXY-059 (250 mg over 1 hour followed by 85 mg/h for 71 hours)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: NXY-059 (500 mg over 1 hour followed by 170 mg/h for 71 hours)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 9227720

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol 24 micrograms twice daily
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 8119517

Group type: EXPERIMENTAL
Intervention: Adaptive AV delay (156 to 63 ms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Fixed AV delay (156 ms)
Number of subjects: 8
Study: 3119693

Group type: EXPERIMENTAL
Intervention: Team‐oriented geriatric assessment by a multidisciplinary team
Number of subjects: 117

Group type: COMPARATOR
Intervention: Traditional care by community internists
Number of subjects: 117
Study: 29528961

Group type: EXPERIMENTAL
Intervention: Supervised resistance training (SUP)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Unsupervised resistance training (UNSUP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both SUP and UNSUP
Number of subjects: 36
Study: 30170586

Group type: EXPERIMENTAL
Intervention: e-Exercise (blended physiotherapy intervention consisting of physiotherapy sessions and a web-application)
Number of subjects: 207

Group type: COMPARATOR
Intervention: usual physiotherapy (control group)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: e-Exercise
Number of subjects: 207
Study: 27632893

Group type: EXPERIMENTAL
Intervention: Preladenant 2 mg BID
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Preladenant 5 mg BID
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Preladenant 10 mg BID
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 24603321

Group type: EXPERIMENTAL
Intervention: Shoes and standard care (deworming with albendazole and health education)
Number of subjects: 915

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 915
Study: 22411658

Group type: EXPERIMENTAL
Intervention: Primary IOL implantation with target postoperative refraction of +8.0 D for infants 28 to 48 days old and +6.0 D for those 49 days or older to younger than 7 months at surgery.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Primary IOL implantation with IOL power of 30.0 D or greater.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Short axial length (<18 mm).
Number of subjects: 49
Study: 18849079

Group type: EXPERIMENTAL
Intervention: Sertraline (or amitriptyline as a second choice) plus Interpersonal Psychotherapy modified for inpatients (IPT)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Sertraline (or amitriptyline as a second choice) plus Clinical Management (CM)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Early improvement within two weeks
Number of subjects: 124
Study: 17202521

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16203762

Group type: EXPERIMENTAL
Intervention: Temozolomide + radiotherapy (n = 287)
Number of subjects: 573

Group type: COMPARATOR
Intervention: Radiotherapy alone (n = 286)
Number of subjects: 573
Study: 12487221

Group type: EXPERIMENTAL
Intervention: DPI (Dry Powder Inhaler) - 200 microg of inhaled budesonide twice daily for 1 month
Number of subjects: 15

Group type: COMPARATOR
Intervention: pMDI + spacer (Pressurized Metered-Dose Inhaler with spacer) - 200 microg of inhaled budesonide twice daily for 1 month
Number of subjects: 15
Study: 9657569

Group type: EXPERIMENTAL
Intervention: 0.2 ppm ozone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 12
Study: 8579313

Group type: EXPERIMENTAL
Intervention: Laser prostatectomy
Number of subjects: 71

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 71
Study: 2560799

Group type: EXPERIMENTAL
Intervention: Hormones plus plasmapheresis
Number of subjects: 2

Group type: COMPARATOR
Intervention: Hormones alone
Number of subjects: 2
Study: 1174138

Group type: EXPERIMENTAL
Intervention: Elemental formula
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard cow milk formula
Number of subjects: 16
Study: 31650487

Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus (PP) by nanoparticle gel phonophoresis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional ultrasound therapy
Number of subjects: 30
Study: 27733079

Group type: EXPERIMENTAL
Intervention: Home-based walking programme with pedometer tracking and tapered coaching calls over 12 weeks
Number of subjects: 123

Group type: COMPARATOR
Intervention: Nutritional counselling with coaching calls over 12 weeks (Control)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Home-based walking programme
Number of subjects: 123
Study: 25933498

Group type: EXPERIMENTAL
Intervention: 30 g of L-glutamine (GLN) daily for 14 days
Number of subjects: 33

Group type: COMPARATOR
Intervention: 30 g of L-alanine (ALA) daily for 14 days
Number of subjects: 33
Study: 24628961

Group type: EXPERIMENTAL
Intervention: Smartphone application for promoting a healthy diet and increased physical activity used for three months
Number of subjects: 1215

Group type: COMPARATOR
Intervention: Standardized intervention on adaptation to the Mediterranean diet and physical activity
Number of subjects: 1215
Study: 22378476

Group type: EXPERIMENTAL
Intervention: Modified Forced-Use Therapy (mFUT)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Modified Constraint-Induced Movement Therapy (mCIMT)
Number of subjects: 37
Study: 19763135

Group type: EXPERIMENTAL
Intervention: EPA treatment (1.8 g administered daily for 3 months)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 17103153

Group type: EXPERIMENTAL
Intervention: 3D SENSE EPI fMRI sequence
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Taste stimuli (lemon juice and chocolate)
Number of subjects: 7
Study: 15306713

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 16087985

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg Zn as sulfate daily)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Stimulation alone (weekly home visits for play demonstration and maternal-child interaction encouragement)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both interventions (zinc supplementation and stimulation)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control (routine care only)
Number of subjects: 114
Study: 10480776

Group type: EXPERIMENTAL
Intervention: DXA-determined adiposity in the abdominal cut at L1-4 level
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: DXA-determined adiposity in the abdominal cut at L1-4 level (lean men)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: BMI and amount of leg fat (obese men)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: AUC I, fat L1-4, diastolic blood pressure (dBP), HDL, and triglyceride
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: fat L1-4 (lean group)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: AUC I and dBP (obese men)
Number of subjects: 87
Study: 8673545

Group type: EXPERIMENTAL
Intervention: L-697,661 as monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-697,661 administered concomitantly with zidovudine (ZDV)
Number of subjects: 0
Study: 1765940

Group type: EXPERIMENTAL
Intervention: Connective tissue graft including the periosteum placed over the furca
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no graft)
Number of subjects: 15
Study: 6749427

Group type: EXPERIMENTAL
Intervention: Cholestyramine (24 g daily) and diet
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo and diet
Number of subjects: 143
Study: 29478886

Group type: EXPERIMENTAL
Intervention: RBC proportion of arachidonic acid (C20:4n-6)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: RBC proportions of dietary polyunsaturated fatty acids (PUFA)
Number of subjects: 344
Study: 29407226

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Physical Therapy Exercise
Number of subjects: 182
Study: 25589511

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate plus glucosamine hydrochloride (CS+GH) 400 mg CS plus 500 mg GH three times a day for 6 months
Number of subjects: 606

Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily for 6 months
Number of subjects: 606

Group type: COMPARATOR
Intervention: CS+GH and Celecoxib
Number of subjects: 606
Study: 25228478

Group type: EXPERIMENTAL
Intervention: 5% Lactobacillus-fermented Chamaecyparis obtusa (LFCO)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 5% Tea Tree Oil (TTO)
Number of subjects: 34
Study: 22535977

Group type: EXPERIMENTAL
Intervention: Insulin withdrawal after 16 hours of hyperglycemia
Number of subjects: 9

Group type: COMPARATOR
Intervention: Insulin infusion after 16 hours of euglycemia
Number of subjects: 9
Study: 20309389

Group type: EXPERIMENTAL
Intervention: Percutaneous adhesiolysis with target delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-participate betamethasone.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Caudal epidural steroid injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution.
Number of subjects: 120
Study: 18832239

Group type: EXPERIMENTAL
Intervention: Single reading with computer‐aided detection
Number of subjects: 31057

Group type: COMPARATOR
Intervention: Double reading
Number of subjects: 31057
Study: 15961678

Group type: EXPERIMENTAL
Intervention: PUFA-supplemented liquid oral diet (3.7 g of PUFA, 1000 mL/d for 5 days preoperatively)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Isocaloric control diet
Number of subjects: 40
Study: 12616980

Group type: EXPERIMENTAL
Intervention: Monophasic oral contraceptive containing 75 micrograms of gestodene and 20 micrograms of ethinyl estradiol
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 150 micrograms of desogestrel and 20 micrograms of ethinyl estradiol
Number of subjects: 95

Group type: COMPARATOR
Intervention: Both oral contraceptives
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Desogestrel-containing oral contraceptive
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Gestodene-containing oral contraceptive
Number of subjects: 95
Study: 10361867

Group type: EXPERIMENTAL
Intervention: 15 mg/d of folic acid and 200 mg/d of pyridoxine for 4 wk
Number of subjects: 20
Study: 7627722

Group type: EXPERIMENTAL
Intervention: Protein-bound polysaccharide P (PSK) therapy
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy plus PSK
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: PSK therapy in patients with abnormal levels of alpha 1-antichymotrypsin and sialic acid
Number of subjects: 158

Group type: COMPARATOR
Intervention: Radiochemotherapy
Number of subjects: 158
Study: 2021332

Group type: EXPERIMENTAL
Intervention: Sulfate free‐electrolyte lavage solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cathartics and enemas
Number of subjects: 60

Group type: COMPARATOR
Intervention: Polyethylene glycol electrolyte lavage solution
Number of subjects: 60
Study: 30953776

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Active control condition (ACC)
Number of subjects: 192
Study: 29038365

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Swimming (HIS, n = 21)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Swimming (MOS, n = 21)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Soccer (SOC, n = 21)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control Group (CON, n = 20)
Number of subjects: 83
Study: 25283485

Group type: EXPERIMENTAL
Intervention: MS+G (metformin-sitagliptin + glargine)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: MG+S (metformin-glargine + sitagliptin)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: MS+G and MG+S
Number of subjects: 194
Study: 23695420

Group type: EXPERIMENTAL
Intervention: Raloxifene (daily for 2 years)
Number of subjects: 71
Study: 21508911

Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity (APA) program, including strength and flexibility training and exercises for improving posture, delivered for 12 months, with 1-hour group classes three times per week.
Number of subjects: 650

Group type: COMPARATOR
Intervention: Not applicable (control group of 310 subjects who did not adhere to the program).
Number of subjects: 650
Study: 19013526

Group type: EXPERIMENTAL
Intervention: 25OHD (25 microg/day) administration for 2 weeks
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 161
Study: 16484698

Group type: EXPERIMENTAL
Intervention: Informed Consent Conference (ICC)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Factors associated with understanding
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Female caregivers and parents of low socioeconomic status
Number of subjects: 84
Study: 15608345

Group type: EXPERIMENTAL
Intervention: Laceback ligatures (experimental group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Non-laceback (control group)
Number of subjects: 62
Study: 11244019

Group type: EXPERIMENTAL
Intervention: ACE inhibition
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102

Group type: COMPARATOR
Intervention: None (baseline comparison)
Number of subjects: 102
Study: 9285506

Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid (GLA)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 8179541

Group type: EXPERIMENTAL
Intervention: Terbutaline (0.25 mg subcutaneously)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Magnesium sulphate (4-g bolus intravenously)
Number of subjects: 46
Study: 2820359

Group type: EXPERIMENTAL
Intervention: Maintenance therapy (alternate-month outpatient)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: No maintenance therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Inpatient induction therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Outpatient induction therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Cyclophosphamide treatment
Number of subjects: 27
Study: 31851858

Group type: EXPERIMENTAL
Intervention: Quiet exposure condition
Number of subjects: 8

Group type: COMPARATOR
Intervention: Speech babble exposure condition
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Referent selection task in quiet
Number of subjects: 8

Group type: COMPARATOR
Intervention: Referent selection task in speech babble
Number of subjects: 8
Study: 30523403

Group type: EXPERIMENTAL
Intervention: LOW intensity (45% VO2max)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MOD intensity (65% VO2max)
Number of subjects: 11
Study: 28189810

Group type: EXPERIMENTAL
Intervention: Intervention (advanced sun protection messages delivered through resort channels)
Number of subjects: 4347

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 4347

Group type: EXPERIMENTAL
Intervention: Intervention (high implementation)
Number of subjects: 4347

Group type: EXPERIMENTAL
Intervention: Intervention (low implementation)
Number of subjects: 4347
Study: 25361220

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiation (nCRT)
Number of subjects: 170

Group type: COMPARATOR
Intervention: surgery alone (group S)
Number of subjects: 170
Study: 23138412

Group type: EXPERIMENTAL
Intervention: Multidisciplinary in-patient rehabilitation programme (3 weeks)
Number of subjects: 95
Study: 22224243

Group type: EXPERIMENTAL
Intervention: Neuromidin as an add-on to basic treatment
Number of subjects: 62

Group type: COMPARATOR
Intervention: Basic treatment (antiaggregant, antihypertensive, cardiac and antidiabetic drugs)
Number of subjects: 62
Study: 19756162

Group type: EXPERIMENTAL
Intervention: Nurse educator‐conducted class on diabetes and hypertension (Group A)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nurse educator‐conducted class and home blood pressure monitoring (Group B)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care (Group C)
Number of subjects: 54
Study: 16542577

Group type: EXPERIMENTAL
Intervention: Cilostazol 200 mg/d
Number of subjects: 120
Study: 15053297

Group type: EXPERIMENTAL
Intervention: Zinc containing infusion
Number of subjects: 5

Group type: COMPARATOR
Intervention: No zinc containing infusion (Control)
Number of subjects: 5
Study: 10835438

Group type: EXPERIMENTAL
Intervention: Nalmefene (60 mg administered as a 10 mg bolus over 15 minutes and then a 50 mg infusion over 23.75 hours)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Nalmefene (in patients <70 years old)
Number of subjects: 368
Study: 9352607

Group type: EXPERIMENTAL
Intervention: German version of the Sickness Impact Profile (SIP)
Number of subjects: 299
Study: 7901056

Group type: EXPERIMENTAL
Intervention: Intravaginal 2.0 mg prostaglandin E2 gel
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Intravaginal 3.0 mg prostaglandin E2 gel
Number of subjects: 167
Study: 3536232

Group type: EXPERIMENTAL
Intervention: Calcitriol (1 microgram daily)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 76
Study: 31184505

Group type: EXPERIMENTAL
Intervention: Mycophenolate
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 28299514

Group type: EXPERIMENTAL
Intervention: CXCR4 peptide antagonist LY2510924 plus carboplatin-etoposide (CE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin-etoposide (CE)
Number of subjects: 0